The Efficacy of Mizoribine (Inosine Monophosphate Dehydrogenase Inhibitor) for ANCA-Associated Vasculitis with Hepatitis B Virus Carrier

Overview

Journal Case Reports Immunol

Publisher Wiley

Specialty Allergy & Immunology

Date 2014 Nov 7

PMID 25374734

Authors

Jun Muratsu

Atsuyuki Morishima

Masayoshi Kukida

Anzu Tanaka

Shigeki Fujita

Katsuhiko Sakaguchi

Affiliations

Soon will be listed here.

Abstract

A 42-year-old female who was an asymptomatic carrier of hepatitis B virus (HBV) was diagnosed with antineutrophil cytoplasm antibody- (ANCA-) associated vasculitis and was induced to remission with 30 mg/day prednisolone nine years ago. Four years ago, she suffered recurrence of ANCA-associated vasculitis and with 30 mg/day prednisolone was induced to remission. This time, laboratory data showed 3-fold increase in myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA) levels. Administration of 30 mg/day prednisolone was started. Three days later, she was admitted to our hospital suffering from fatigue. After admission, urinalysis showed glomerular hematuria. Despite administration of 30 mg/day prednisolone, MPO-ANCA titer had been of high level, ranging from 42 to 83 EU for 2.5 months. Furthermore, the adverse effects of steroid were seen. We decided the tapering of prednisolone (25 mg/day) and the start of mizoribine (4-carbamoyl-1-β-D-ribofuranosyl imidazolium-5-olate) administration. After mizoribine treatment, MPO-ANCA titer was decreased without any mizoribine-related adverse effects. Six months later, MPO-ANCA titer was decreased to normal levels and she was induced to clinical remission without reactivation of HBV. We describe the effectiveness of mizoribine for the ANCA-associated vasculitis complicated with HBV-carrier.

References

Yoshioka K, Ohashi Y, Sakai T, Ito H, Yoshikawa N, Nakamura H . A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int. 2000; 58(1):317-24. DOI: 10.1046/j.1523-1755.2000.00168.x. View

Livonesi M, Moro de Sousa R, Figueiredo L . In vitro study of antiviral activity of mycophenolic acid on Brazilian orthobunyaviruses. Intervirology. 2007; 50(3):204-8. DOI: 10.1159/000099219. View

Park M, Park Y, Jung S, Chung I, Choi K, Lee S . Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus. 2004; 13(8):569-74. DOI: 10.1191/0961203304lu1063oa. View

Markland W, McQuaid T, Jain J, Kwong A . Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother. 2000; 44(4):859-66. PMC: 89783. DOI: 10.1128/AAC.44.4.859-866.2000. View

Lok A, McMahon B . Chronic hepatitis B. Hepatology. 2007; 45(2):507-39. DOI: 10.1002/hep.21513. View

Cheng A, Hsiung C, Su I, Chen P, Chang M, Tsao C . Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003; 37(6):1320-8. DOI: 10.1053/jhep.2003.50220. View

Nishioka Y, Horita Y, Tadokoro M, Taura K, Suyama N, Miyazaki M . Mizoribine induces remission of relapsed ANCA-associated renal vasculitis. Nephrol Dial Transplant. 2005; 21(4):1087-8. DOI: 10.1093/ndt/gfi295. View

Hirayama K, Kobayashi M, Hashimoto Y, Usui J, Shimizu Y, Hirayama A . Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis. 2004; 44(1):57-63. DOI: 10.1053/j.ajkd.2004.03.030. View

Lok A, Liang R, Chiu E, Wong K, Chan T, Todd D . Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991; 100(1):182-8. DOI: 10.1016/0016-5085(91)90599-g. View

10.

Hader J, Marzella L, Myers R, Jacobs S, Naslund M . Hyperbaric oxygen treatment for experimental cyclophosphamide-induced hemorrhagic cystitis. J Urol. 1993; 149(6):1617-21. DOI: 10.1016/s0022-5347(17)36462-5. View

11.

Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H . Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transplant Proc. 1996; 28(6):3643-8. View

12.

Franchetti P, Grifantini M . Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents. Curr Med Chem. 1999; 6(7):599-614. View

13.

Turnbull J, Harper L . Adverse effects of therapy for ANCA-associated vasculitis. Best Pract Res Clin Rheumatol. 2009; 23(3):391-401. DOI: 10.1016/j.berh.2009.04.002. View

14.

Kuramoto T, Daikoku T, Yoshida Y, Takemoto M, Oshima K, Eizuru Y . Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. J Pharmacol Exp Ther. 2010; 333(3):816-21. DOI: 10.1124/jpet.109.160630. View

15.

Kaneko K, Nagaoka R, Ohtomo Y, Yamashiro Y . Mizoribine for childhood IgA nephropathy. Nephron. 1999; 83(4):376-7. DOI: 10.1159/000045438. View

16.

Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M . Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab. 2005; 23(2):105-9. DOI: 10.1007/s00774-004-0596-x. View

17.

Gong Z, De Meyer S, Clarysse C, Verslype C, Neyts J, De Clercq E . Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat. 1999; 6(3):229-36. DOI: 10.1046/j.1365-2893.1999.00163.x. View

18.

Padalko E, Verbeken E, Matthys P, Aerts J, De Clercq E, Neyts J . Mycophenolate mofetil inhibits the development of Coxsackie B3-virus-induced myocarditis in mice. BMC Microbiol. 2003; 3:25. PMC: 317291. DOI: 10.1186/1471-2180-3-25. View

19.

Ichimura H, Levy J . Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology. 1995; 211(2):554-60. DOI: 10.1006/viro.1995.1437. View